NASDAQ:CELZ Creative Medical Technology (CELZ) Stock Price, News & Analysis → The 'Smart Money' Is Ready for May 1st Are You? (From Stansberry Research) (Ad) Free CELZ Stock Alerts $4.81 -0.01 (-0.21%) (As of 01:30 PM ET) Add Compare Share Share Today's Range$4.81▼$4.8950-Day Range$4.03▼$6.4552-Week Range$3.93▼$10.28Volume7,503 shsAverage Volume166,834 shsMarket Capitalization$6.54 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media Get Creative Medical Technology alerts: Email Address Creative Medical Technology MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy2.17% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.95Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.68) to ($3.77) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.96 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Creative Medical Technology. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.17% of the float of Creative Medical Technology has been sold short.Short Interest Ratio / Days to CoverCreative Medical Technology has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Creative Medical Technology has recently decreased by 30.84%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCreative Medical Technology does not currently pay a dividend.Dividend GrowthCreative Medical Technology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CELZ. Previous Next 2.7 News and Social Media Coverage News SentimentCreative Medical Technology has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Creative Medical Technology this week, compared to 0 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Creative Medical Technology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.30% of the stock of Creative Medical Technology is held by insiders.Percentage Held by InstitutionsOnly 1.42% of the stock of Creative Medical Technology is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Creative Medical Technology are expected to grow in the coming year, from ($4.68) to ($3.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Creative Medical Technology is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Creative Medical Technology is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCreative Medical Technology has a P/B Ratio of 0.64. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchHow to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."Get the full story here. About Creative Medical Technology Stock (NASDAQ:CELZ)Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.Read More CELZ Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CELZ Stock News HeadlinesApril 24, 2024 | morningstar.comCreative Medical Technology Holdings Inc CELZApril 19, 2024 | americanbankingnews.comComparing Zura Bio (NASDAQ:ZURA) & Creative Medical Technology (NASDAQ:CELZ)April 24, 2024 | Stansberry Research (Ad)How to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."March 24, 2024 | finance.yahoo.comCreative Medical Technology Holdings Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsMarch 18, 2024 | forbes.comMedical Practices And Branding In A Digital AgeMarch 18, 2024 | theglobeandmail.comCreative Medical Technology Skyrockets on Word of New Diabetes MedicationMarch 7, 2024 | msn.comWhy Is Diabetes Focused Creative Medical Stock Surging On Thursday?March 7, 2024 | markets.businessinsider.comCreative Medical Announces FDA Authorization For Expanded Access For CELZ-201; Stock UpApril 24, 2024 | Stansberry Research (Ad)How to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."March 7, 2024 | marketwatch.comCreative Medical Shares Rise 37% After FDA Authorization for CELZ-201March 7, 2024 | msn.comCreative Medical stock rallies for second day on FDA updatesMarch 7, 2024 | finance.yahoo.comCreative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded AccessMarch 6, 2024 | morningstar.comCreative Medical Technology Holdings IncMarch 6, 2024 | markets.businessinsider.comCreative Medical Receives FDA Orphan Drug Designation For CELZ-101; Stock Up In Pre-marketMarch 6, 2024 | marketwatch.comCreative Medical Shares Rally Premarket on FDA Orphan DesignationMarch 6, 2024 | msn.comCreative Medical stock rallies 18% on FDA orphan drug designationMarch 6, 2024 | businesswire.comCreative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation TherapyFebruary 15, 2024 | investing.comCreative Medical Technology Holdings Inc (CELZ)February 9, 2024 | benzinga.comSteven L White's Net WorthDecember 20, 2023 | finance.yahoo.comCreative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back PainOctober 11, 2023 | msn.comCreative Medical to initiate trial of lower back pain treatmentOctober 10, 2023 | markets.businessinsider.comCreative Medical Gets IRB Approval For StemSpine Trial Using AlloStem Cell TherapyOctober 10, 2023 | finance.yahoo.comCreative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back PainSeptember 22, 2023 | finance.yahoo.comWhat Makes Creative Medical Technology Holdings, Inc. (CELZ) a New Buy StockSeptember 19, 2023 | finance.yahoo.comCreative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back PainAugust 24, 2023 | finance.yahoo.comWhat Is Allogeneic Cell Therapy, And What’s Driving This Market’s 25%+ Annual Global Growth?August 23, 2023 | benzinga.comWhat Is Allogeneic Cell Therapy, And What's Driving This Market's 25%+ Annual Global Growth?See More Headlines Receive CELZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Creative Medical Technology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/22/2024Today4/24/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CELZ CUSIPN/A CIK1187953 Webwww.creativemedicaltechnology.com Phone(833) 336-7636FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,290,000.00 Net MarginsN/A Pretax Margin-58,744.45% Return on Equity-41.48% Return on Assets-40.22% Debt Debt-to-Equity RatioN/A Current Ratio27.68 Quick Ratio27.67 Sales & Book Value Annual Sales$10,000.00 Price / Sales655.52 Cash FlowN/A Price / Cash FlowN/A Book Value$7.48 per share Price / Book0.64Miscellaneous Outstanding Shares1,360,000Free Float1,312,000Market Cap$6.56 million OptionableNot Optionable Beta2.20 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Timothy Warbington (Age 62)Co-Founder, Chairman, President & CEO Comp: $429kMr. Donald Dickerson (Age 59)Senior VP, CFO & Director Comp: $390kKey CompetitorsTitan PharmaceuticalsNASDAQ:TTNPChromocell TherapeuticsNYSE:CHROFresh Tracks TherapeuticsNASDAQ:FRTXGamida CellNASDAQ:GMDATRACON PharmaceuticalsNASDAQ:TCONView All CompetitorsInsidersTimothy WarbingtonBought 800 shares on 6/27/2023Total: $3,552.00 ($4.44/share)View All Insider Transactions CELZ Stock Analysis - Frequently Asked Questions How have CELZ shares performed in 2024? Creative Medical Technology's stock was trading at $4.61 on January 1st, 2024. Since then, CELZ shares have increased by 4.3% and is now trading at $4.81. View the best growth stocks for 2024 here. Are investors shorting Creative Medical Technology? Creative Medical Technology saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 28,700 shares, a drop of 30.8% from the March 15th total of 41,500 shares. Based on an average daily trading volume, of 200,700 shares, the days-to-cover ratio is presently 0.1 days. Currently, 2.2% of the shares of the company are short sold. View Creative Medical Technology's Short Interest. When is Creative Medical Technology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our CELZ earnings forecast. How were Creative Medical Technology's earnings last quarter? Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) released its earnings results on Friday, March, 22nd. The company reported ($1.21) EPS for the quarter, missing analysts' consensus estimates of ($1.13) by $0.08. When did Creative Medical Technology's stock split? Creative Medical Technology's stock reverse split before market open on Sunday, June 11th 2023. The 1-10 reverse split was announced on Sunday, June 11th 2023. The number of shares owned by shareholders was adjusted after the market closes on Sunday, June 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Creative Medical Technology? Shares of CELZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CELZ) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority Goldtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Creative Medical Technology Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.